Effects of renal denervation on insulin resistance

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 11, 2012, Pages 1381-1386

  Hering, Dagmara ^a,b   Esler, Murray D ^c   Schlaich, Markus P ^a,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c MONASH UNIVERSITY   (Australia)

Author keywords

diabetes; hypertension; insulin resistance; obesity; renal denervation; sympathetic activity

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLUCOSE; INSULIN; NEBIVOLOL; NORADRENALIN;

ADRENERGIC SYSTEM; ATHEROGENESIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CATHETER ABLATION; COMORBIDITY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HUMAN; HYPERINSULINEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN METABOLISM; INSULIN RESISTANCE; KIDNEY DENERVATION; METABOLIC SYNDROME X; MORBIDITY; MUSCLE INNERVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; RENOVASCULAR HYPERTENSION; RESISTANT HYPERTENSION; REVIEW; SYMPATHETIC INNERVATION; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DIABETIC NEPHROPATHIES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; HYPERTENSION; INSULIN RESISTANCE; KIDNEY; SYMPATHECTOMY;

EID: 84871302177     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.140     Document Type: Review

References (44)

1. WHO. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. WHO (2009).
2. Dean N, Shuaib A. Hypertension: the most important preventable risk factor for cerebrovascular disease. Lancet Neurol. 10(7), 606-607 (2011).
3. Mancia G, De Backer G, Dominiczak A et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25(6), 1105-1187 (2007).
4. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N. Engl. J. Med. 342(13), 905-912 (2000).
5. Weycker D, Nichols GA, O'Keeffe-Rosetti M et al. Excess risk of diabetes in persons with hypertension. J. Diabetes Complicat. 23(5), 330-336 (2009).
6. Verdecchia P, Reboldi G, Angeli F et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43(5), 963-969 (2004).
7. Inzucchi SE, Bergenstal RM, Buse JB et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in Type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6), 1364-1379 (2012).
8. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 94(3), 311-321 (2011).
9. Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N. Engl. J. Med. 317(6), 350-357 (1987).
10. Weidmann P, Böhlen L, de Courten M. Insulin resistance and hyperinsulinemia in hypertension. J. Hypertens. Suppl. 13(2), S65-S72 (1995).
11. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J. Clin. Invest. 55(4), 845-855 (1975).
12. Schwartz J, Brumbaugh RC, Chiu M. Short stature, growth hormone, insulinlike growth factors, and serum proteins in the Mountain Ok people of Papua New Guinea. J. Clin. Endocrinol. Metab. 65(5), 901-905 (1987).
13. Sechi LA. Mechanisms of insulin resistance in rat models of hypertension and their relationships with salt sensitivity. J. Hypertens. 17(9), 1229-1237 (1999).
14. Rocchini AP. Obesity hypertension, salt sensitivity and insulin resistance. Nutr. Metab. Cardiovasc. Dis. 10(5), 287-294 (2000).
15. Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J. Hypertens. 22(12), 2363-2369 (2004).
16. Grassi G, Dell'Oro R, Quarti-Trevano F et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 48(7), 1359-1365 (2005).
17. Straznicky NE, Eikelis N, Lambert EA, Esler MD. Mediators of sympathetic activation in metabolic syndrome obesity. Curr. Hypertens. Rep. 10(6), 440-447 (2008).
18. Straznicky NE, Lambert GW, Masuo K et al. Blunted sympathetic neural response to oral glucose in obese subjects with the insulin-resistant metabolic syndrome. Am. J. Clin. Nutr. 89(1), 27-36 (2009).
19. Lembo G, Capaldo B, Rendina V et al. Acute noradrenergic activation induces insulin resistance in human skeletal muscle. Am. J. Physiol. 266(2 Pt 1), E242-E247 (1994).
20. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 21(5), 618-623 (1993).
21. Julius S, Gudbrandsson T, Jamerson K, Andersson O. The interconnection between sympathetics, microcirculation, and insulin resistance in hypertension. Blood Press. 1(1), 9-19 (1992).
22. Egan BM. Neurohumoral, hemodynamic and microvascular changes as mechanisms of insulin resistance in hypertension: a provocative but partial picture. Int. J. Obes. 15(Suppl. 2), 133-139 (1991).
23. Esler M, Lambert G, Brunner-La Rocca HP, Vaddadi G, Kaye D. Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice. Acta Physiol. Scand. 177(3), 275-284 (2003).
24. Straznicky NE, Lambert GW, McGrane MT et al. Weight loss may reverse blunted sympathetic neural responsiveness to glucose ingestion in obese subjects with metabolic syndrome. Diabetes 58(5), 1126-1132 (2009).
25. Straznicky NE, Grima MT, Sari CI et al. Neuroadrenergic dysfunction along the diabetes continuum: a comparative study in obese metabolic syndrome subjects. Diabetes 61(10), 2506-2516 (2012).
26. Luippold G, Beilharz M, Mühlbauer B. Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol. Dial. Transplant. 19(2), 342-347 (2004).
27. Salman IM, Ameer OZ, Sattar MA et al. Renal sympathetic nervous system hyperactivity in early streptozotocininduced diabetic kidney disease. Neurourol. Urodyn. 30(3), 438-446 (2011).
28. DiBona GF. The sympathetic nervous system and hypertension: recent developments. Hypertension 43(2), 147-150 (2004).
29. Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia 53(10), 2093-2104 (2010).
30. Huang WC, Fang TC, Cheng JT. Renal denervation prevents and reverses hyperinsulinemia-induced hypertension in rats. Hypertension 32(2), 249-254 (1998).
31. Coimbra TM, Janssen U, Gröne HJ et al. Early events leading to renal injury in obese Zucker (fatty) rats with Type II diabetes. Kidney Int. 57(1), 167-182 (2000).
32. Shiota M, Printz RL. Diabetes in Zucker diabetic fatty rat. Methods Mol. Biol. 933, 103-123 (2012).
33. Toblli JE, Cao G, Giani JF, Muñoz MC, Angerosa M, Dominici FP. Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats. J. Hypertens. 29(8), 1613-1623 (2011).
34. Schmieder RE, Redon J, Grassi G et al. ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J. Hypertens. 30(5), 837-841 (2012).
35. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373(9671), 1275-1281 (2009).
36. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57(5), 911-917 (2011).
37. Witkowski A, Prejbisz A, Florczak E et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 58(4), 559-565 (2011).
38. Hering D, Walton A, Krum H, Lambert GW, Esler MD, Schlaich MP. Renal nerve ablation reduces blood pressure in a patient with renovascular hypertension resistant to drug and revascularisation therapies. Int. J. Cardiol. 159(2), e35-e36 (2012).
39. Brandt MC, Mahfoud F, Reda S et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J. Am. Coll. Cardiol. 59(10), 901-909 (2012).
40. Hering D, Mahfoud F, Walton AS et al. Renal denervation in moderate to severe CKD. J. Am. Soc. Nephrol. 23(7), 1250-1257 (2012).
41. Mahfoud F, Schlaich M, Kindermann I et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123(18), 1940-1946 (2011).
42. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32(7), 1327-1334 (2009).
43. Schlaich MP, Straznicky N, Grima M et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J. Hypertens. 29(5), 991-996 (2011).
44. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J. Clin. Invest. 96(4), 1897-1904 (1995).